4 Sullivan, eugene jeffrey May 26, 2015
4 Schaeffer, orlov s nicole May 26, 2015
4 Pellizzari, christine a May 26, 2015
4 Lewis, william May 26, 2015
4 Drechsler, andrew t May 26, 2015
IsoRay reports that the survival rate at 5 years was 100% for Cesium-131 lung cancer treatment group, which included many high risk patients, and Cesium-131 added no noticeable side effects (ISR) :
The study noted that the survival rate at 5 years was exceptional for the Cesium-131 group, which included many high risk patients, and Cesium-131 added no noticeable side effects. Treatment with Cesium-131 was performed at the time of the surgery as a single treatment, in contrast to another treatment option, external radiation, which requires numerous hospital visit.
Anyone following this stock? Looks like has great growth potential.
"We are extremely pleased with the growth of Forfivo XL(R) throughout 2014 and we believe that this growth will continue, especially as Edgemont increased its salesforce threefold in mid-December, 2014" stated Dr. Horst G. Zerbe, President and CEO of IntelGenx. "The marketing and sales efforts that our partner, Edgemont Pharmaceuticals, has invested in the commercialization of Forfivo XL(R) have ensured that a more convenient and safe alternative for patients requiring high-dose anti-depressant therapy is widely available in the US. Forfivo XL(R) generated in excess of $1.1 million (unaudited) of revenue for IntelGenx in 2014 and we anticipate significantly higher revenue from the product in 2015."
April 25 (Reuters) - Cytokinetics Inc said its experimental treatment for Lou Gehrig's disease - a progressive neurodegenerative disorder - failed the main goal in a mid-stage trial.
The study tested the efficacy of the drug, tirasemtiv - one of the company's lead compounds - against a placebo in 711 patients with amyotrophic lateral sclerosis (ALS).
The San Francisco-based company's stock was halted before the bell on Friday.
9 Deer Park Drive, Suite C
Monmouth Junction, NJ 08852-1923
ANNUAL MEETING OF SHAREHOLDERS
April 17, 2014
To the Shareholders:
We cordially invite you to attend the 2014 Annual Meeting of Shareholders to be held at the Bridgewater Marriott, 700 Commons Way, Bridgewater, New Jersey 08807, on May 29, 2014, at 9:00 a.m. local time (the "Annual Meeting"). A formal notice of the meeting, together with a proxy statement and proxy form, is enclosed with this letter. The notice points out that you will be asked to:
elect two Class II directors, Donald Hayden, Jr. and David W.J. McGirr, to serve until the 2017 Annual Meeting of Shareholders;
conduct an advisory vote on the compensation of our named executive officers;
ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2014; and
transact such other business as may properly come before the meeting.
Please read the notice and proxy statement carefully, and vote by telephone, electronically through the Internet, by completing, signing and mailing the enclosed proxy card promptly, or in person at the Annual Meeting.
Jan 14, 2014
Form 4 / Drechsler, Andrew T
Form 4 / Gupta, Renu
Form 4 / Lewis, William
Form 4 / Pellizzari, Christine A
Form 4 / Pauls, Matthew
Jan 14, 2014
Form 4 / Engelsen, Steinar J
Form 4 / Hayden, Donald J Jr
Form 4 / Altomari, Alfred
Form 4 / Sharoky, Melvin Md
Form 4 / Mcgirr, David W J
Form 4 / Whitcomb, Randall W
View all SEC Filings
By combining these two therapies, researchers found that in addition to increased body and muscle weight, mice showed enhanced locomotory capacities and remarkable improvement in muscle pathology. The most impressive outcome was the significant resolution of inflammation and fibrosis, not seen with single mode therapies. The research team concluded that the use of this combination therapy is an effective treatment for MDC1A, highlighting a compelling argument that a combinatorial approach has a synergistic benefit and could have the potential of treating patients with congenital muscular dystrophy.
The study was led by Mahasweta Girgenrath, PhD, assistant professor and director of the Muscle Disorders and Regenerative Biology Laboratory at BU Sargent College's Department of Health Sciences. Boston University (BU) researchers and postdoctoral fellows Jenny Yamauchi, Ajay Kumar, Lina Duarte, and Thomas Mehuron were collaborators on this study.
Muscular Dystrophy type 1A (MDC1A) is the second most common form of congenital muscular dystrophy. Patients with this disease have poor muscle tone at birth, extremely compromised neuromuscular function, and are rarely able to walk independently. Most patients with MDC1A succumb to a premature death due to either respiratory complications or failure to thrive. Although significant strides have been made towards understanding the molecular and biochemical mechanisms underlying MDC1A, there remains no effective therapy in place to combat this lethal disease.
The research team, led by Girgenrath, hypothesized that the complex pathology seen in MDC1A may be the result of dysregulation of multiple cellular functions and processes, meaning that strategies which simultaneously target several of those mechanisms might lead to a reduction of symptoms.
"Very few studies have utilized the power of combinatorial therapy in the context of muscular dystrophy." said Professor Girgenrath, the study's corresponding author. "While most MD treatments are single-target therapies, we're delving into combinations of different therapies to target multiple pathways."
The research team studied the outcome of combining the following single mode treatments: increasing regeneration, by overexpressing muscle specific insulin like growth factor-1, IGF-1 and preventing cell death, by inhibiting the expression of Bax, a pro-apoptotic protein. In addition, to test the translational potential of this combination therapy, the researchers systemically treated Bax deficient dystrophic mice with recombinant human IGF-1 (IPLEX TM, manufactured by Insmed)